ARTICLE | Clinical News
WF10: Phase III trial update
April 12, 1999 7:00 AM UTC
Oxo Chemie Inc., South San Francisco, Calif. Product: WF10 Business: Infectious diseases Therapeutic category: Immune modulation Target: Macrophages Description: Tetrachlorodecaoxygen chlorite matrix...